Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Canada, China, Denmark, France, Germany, India, Italy, Spain, Sweden, United Kingdom
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Infertility|Infertility, Female|Infertility, Male
Phase 2: Asthenozoospermia|Central Cord Syndrome|Ovarian Hyperstimulation Syndrome|Pregnancy Outcomes|Pregnancy, Ovarian
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07153367 |
RISE | P2 |
Recruiting |
Infertility |
2027-12-17 |
50% |
2025-12-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT06997900 |
MARCS 2 | P2 |
Recruiting |
Central Cord Syndrome|Ovarian Hyperstimulation Syndrome|Pregnancy Outcomes|Pregnancy, Ovarian |
2026-08-01 |
50% |
2025-08-01 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2023-508430-34-00 |
2023-508430-34-00 | P2 |
Completed |
Infertility, Male|Asthenozoospermia |
2024-10-23 |
2025-05-02 |
Treatments |
|
NCT06173869 |
COCO | P3 |
Completed |
Infertility, Male|Infertility, Female |
2025-05-31 |
29% |
2025-06-13 |
|
NCT05263388 |
ADAPT-1 | P3 |
Completed |
Infertility |
2024-04-16 |
18% |
2025-04-03 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
2021-001785-38 |
ADAPT-1 | P3 |
Active, not recruiting |
Infertility |
2024-02-19 |
2025-07-04 |
Treatments |
|
NCT04773353 |
IRIS | P3 |
Completed |
Infertility |
2023-12-12 |
35% |
2024-02-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date |